Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Yinxiang Wang | Executive Chairman & CEO | 432.07k | -- | 1965 |
| Ms. Xiaojie Wang | Executive Director & President of Administration | 322.41k | -- | 1965 |
| Ms. Yunyan Hu | Executive VP & Executive Director | 322.41k | -- | 1962 |
| Ms. Tao Yang | Vice President of Human Resources | -- | -- | -- |
| Dr. Andrea Wang-Gillam M.D., Ph.D. | Executive VP, Chief Medical Officer and Global Head of R&D | -- | -- | 1971 |
| Ms. Yanping Wang | Executive Vice President of Non-Clinical R&D | -- | -- | -- |
| Dr. Haijun Wang | Senior Vice President of Information & Data Management | -- | -- | -- |
| Ms. Yuli Ding | Executive Vice President of Clinical Development | -- | -- | -- |
| Ms. Qing Xue | Joint Company Secretary | -- | -- | 1989 |
| Mr. Ming Fai Chung CPA | Joint Company Secretary | -- | -- | 1979 |
Jacobio Pharmaceuticals Group Co., Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 298
Description
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. The company's drug development programs include Glecirasib (JAB-21822), a KRAS G12C inhibitor currently under multiple stage studies for indications, including NSCLC, PDAC, CRC and other solid tumors; JAB-3068, an SHP2 inhibitor approved by the FDA to enter clinical development for the treatment of esophageal cancer, including esophageal squamous cell carcinoma; and JAB-3312, an SHP2 inhibitor with multiple indications, such as KRAS G12C mut NSCLC under Phase III pivotal study, and Osimertinib progressed NSCLC under Phase I study, as well as NSCLC, HNSCC, and ESCC under Phase IIa studies. It also develops JAB-23E73 currently under IND-enabling studies for targeting multiple KRAS mutants indicated for PDAC, CRC, and NSCLC; JAB-BX300, a self-developed LIF mAb, under IND study indicated for the treatment of solid tumors; JAB-22000, a small-molecule KRAS G12D inhibitor, under lead optimization study indicated for PDAC, CRC, and NSCLC treatments; and JAB-8263, a Bromodomain and Extra-Terminal motif (BET) inhibitor, under Phase I studies indicated for MF, AML, and solid tumor. In addition, the company is involved in the development of JAB-2485, an Aurora Kinase A inhibitor, under Phase I study indicated for the treatment of solid tumors; JAB-24114, a glutamine-utilizing enzyme inhibitor under IND study indicated for the treatment of solid tumors; and JAB-30355, an orally bioavailable small molecule activator under IND study for the treatment of patients with locally advanced or metastatic solid tumors. It has a license and collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors; and with Shanghai Allist Pharmaceuticals Co., Ltd. to research, develop, manufacture, and commercialize Glecirasib and JAB-3312. The company was founded in 2015 and is headquartered in Beijing, China.
Corporate Governance
Upcoming Events
March 26, 2025 at 10:59 AM UTC - March 31, 2025 at 12:00 PM UTC
Jacobio Pharmaceuticals Group Co., Ltd. Earnings Date
Recent Events
Recent Events Information Not Available